NO802751L - Hybrid cellelinje for fremstilling av monoclonalt antistoff til cytotoksiske og suppressor t-celler hos mennesker, samt fremgangsmaate til fremstilling av antistoffet - Google Patents

Hybrid cellelinje for fremstilling av monoclonalt antistoff til cytotoksiske og suppressor t-celler hos mennesker, samt fremgangsmaate til fremstilling av antistoffet

Info

Publication number
NO802751L
NO802751L NO802751A NO802751A NO802751L NO 802751 L NO802751 L NO 802751L NO 802751 A NO802751 A NO 802751A NO 802751 A NO802751 A NO 802751A NO 802751 L NO802751 L NO 802751L
Authority
NO
Norway
Prior art keywords
suppressor
cytotoxic
humans
cells
procedure
Prior art date
Application number
NO802751A
Other languages
English (en)
Other versions
NO159884C (no
NO159884B (no
Inventor
Patrick Chung-Shu Kung
Gideon Goldstein
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26758322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO802751(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO802751L publication Critical patent/NO802751L/no
Publication of NO159884B publication Critical patent/NO159884B/no
Publication of NO159884C publication Critical patent/NO159884C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO802751A 1979-09-18 1980-09-17 Monoklonalt antistoff. NO159884C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7664279A 1979-09-18 1979-09-18
US06/082,515 US4364932A (en) 1979-09-18 1979-10-09 Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same

Publications (3)

Publication Number Publication Date
NO802751L true NO802751L (no) 1981-03-19
NO159884B NO159884B (no) 1988-11-07
NO159884C NO159884C (no) 1989-02-15

Family

ID=26758322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO802751A NO159884C (no) 1979-09-18 1980-09-17 Monoklonalt antistoff.

Country Status (19)

Country Link
US (1) US4364932A (no)
EP (1) EP0025722B2 (no)
AU (1) AU537806B2 (no)
CA (1) CA1170593A (no)
DE (2) DE25722T1 (no)
DK (1) DK154566C (no)
ES (1) ES8200559A1 (no)
FI (1) FI75364C (no)
GR (1) GR70286B (no)
HK (1) HK23986A (no)
IE (1) IE50534B1 (no)
IL (1) IL61063A (no)
MY (1) MY8600515A (no)
NO (1) NO159884C (no)
NZ (1) NZ194982A (no)
PH (1) PH16567A (no)
PT (1) PT71814B (no)
SG (1) SG6386G (no)
YU (1) YU44411B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4637983A (en) * 1979-10-09 1987-01-20 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor T cells, antibody, and methods
US4803262A (en) * 1979-10-09 1989-02-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor T cells, antibody, and methods
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4524025A (en) * 1982-06-30 1985-06-18 E. I. Du Pont De Nemours And Company Hybridoma cell lines and monoclonal antibodies to theophylline
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US4649106A (en) * 1984-06-01 1987-03-10 Dana-Farber Cancer Institute, Inc. Distinguishing subsets of human cells
JPS6179164A (ja) * 1984-09-26 1986-04-22 Amano Pharmaceut Co Ltd 抗原抗体反応の短縮方法
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
ATE82588T1 (de) * 1986-04-28 1992-12-15 Endotronics Inc Zuchtverfahren fuer leukocyten.
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5085985A (en) * 1987-11-12 1992-02-04 Becton Dickinson & Co. Monoclonal antibodies and their use in a method for monitoring subsets of activated T cells
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
WO1999025734A2 (en) * 1997-11-13 1999-05-27 Schering Corporation Th2 CELL DEPLETION; COMPOSITIONS; METHODS
US6498006B2 (en) 1997-11-24 2002-12-24 Johnson T. Wong Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
US7653260B2 (en) 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
PT71814A (en) 1980-10-01
DK154566C (da) 1989-04-17
DK394880A (da) 1981-03-19
FI75364B (fi) 1988-02-29
CA1170593A (en) 1984-07-10
FI802917A (fi) 1981-03-19
IL61063A0 (en) 1980-11-30
EP0025722A2 (en) 1981-03-25
NZ194982A (en) 1983-02-15
IL61063A (en) 1984-04-30
HK23986A (en) 1986-04-11
FI75364C (fi) 1988-06-09
DK154566B (da) 1988-11-28
EP0025722A3 (en) 1981-11-04
ES495165A0 (es) 1981-11-16
EP0025722B2 (en) 1999-04-14
YU44411B (en) 1990-08-31
NO159884C (no) 1989-02-15
US4364932A (en) 1982-12-21
NO159884B (no) 1988-11-07
IE50534B1 (en) 1986-05-14
SG6386G (en) 1986-11-21
AU537806B2 (en) 1984-07-12
IE801944L (en) 1981-03-18
EP0025722B1 (en) 1985-05-22
DE3070669D1 (en) 1985-06-27
PH16567A (en) 1983-11-18
MY8600515A (en) 1986-12-31
YU239280A (en) 1984-04-30
DE25722T1 (de) 1984-07-19
ES8200559A1 (es) 1981-11-16
PT71814B (en) 1982-03-26
GR70286B (no) 1982-09-03
AU6247680A (en) 1981-04-09

Similar Documents

Publication Publication Date Title
NO802751L (no) Hybrid cellelinje for fremstilling av monoclonalt antistoff til cytotoksiske og suppressor t-celler hos mennesker, samt fremgangsmaate til fremstilling av antistoffet
PH16642A (en) Complement-fixing monoclonal antibody to human t cells,and methods of preparing same
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
NO165961C (no) Fremgangsmaate til fremstilling av interferonproteiner.
NO843293L (no) Monoklonale antistoffer, samt fremgangsmaate for fremstilling av slike
AU525724B2 (en) Hybridoma antibodies
IT8124862A0 (it) Produzione di anticorpi monoclonali umani mediante ibridomi umani.
DK199783D0 (da) Immunoglobulin-halvmolekyler og fremgangsmade til fremstilling af hybrid-antistoffer
NO168370C (no) Kontinuerlig fremgangsmaate til fremstilling av encelleprotein-materiale
NL190473C (nl) Werkwijze voor het bereiden van immunoglobulinepreparaten.
NL7706070A (nl) Inrichting voor de vervaardiging van samenge- stelde liggers.
IT1203316B (it) Gruppo e procedimento per la trasformazione di un cambio di velocita per autoveicoli e cambio di velocita ottenuto mediante tale trasformazione
JPS5685287A (en) Production of monoclonal antibody
IT7826676A0 (it) Procedimento per la preparazione di cellule di placenta defibrinizzate e liofilizzate.
DK37382A (da) Fremgangsmaade til fremstilling af hybridceller,der producereret antistof,fremgangsmaade til fremstilling af antistoffer samt hybridceller og antistoffer
NO802284L (no) Sementklinker og fremgangsmaate for fremstilling av denne
JPS5695118A (en) Hybrid cell line* antibody and method for manufacturing monoclonal antibody to human cell toxicity and suppressor t cell
RO80299A (ro) Procedeu pentru prepararea unor imidazolil enol-eteri
BE892296A (fr) Anticorps monoclonaux
NL7812616A (nl) Antibioticum van het peptidetype; werkwijze voor de be- reiding daarvan.
NO874799D0 (no) Fremgangsmaate for fremstilling av monoklonale antistoffer ved dyrking av hybridom-cellelinjen lym-2.
HRP940786B1 (en) Hybrid cell line for production of monoclonal antibody for human cytotoxic and supressor t cells, antibody and process
NO874798L (no) Fremgangsmaate for fremstilling av monoklonale antistofferved dyrking av hybridom-cellelinjen lym-1.
NO884472D0 (no) Antistoffer og fremgangsmaater for fremstilling derav.
ATE13446T1 (de) Monoklonaler antikoerper gegen menschliche zytotoxische und suppressor-t-zellen und verfahren zu dessen herstellung.